Product Description: Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium[1][2].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Hassan R, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20(23):5927-5936. /[2]Baldo P, et al. Amatuximab and novel agents targeting mesothelin for solid tumors. Onco Targets Ther. 2017;10:5337-5353. Published 2017 Nov 8.
CAS Number: 931402-35-6
Molecular Weight: N/A
Compound Purity: 99.90
Research Area: Cancer
Solubility: H2O
Target: Mesothelin
English
Deutsch
